1stOncology™: Cancer Intelligence Service – Page 11593 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Mylan to Release 2019 Fourth Quarter, Full Year Results and 2020 Guidance on Feb. 27, 2020

On February 18, 2020 Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) reported that it will release its fourth quarter and full year 2019 financial results, as well as its 2020 financial guidance, on Thursday, Feb. 27, after the close of the U.S. financial markets (Press release, Mylan, FEB 18, 2020, View Source [SID1234554472]). The company also will host a webcast at 4:30 p.m. ET on Feb. 27 to discuss the results and 2020 guidance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The briefing can be accessed live by calling 855.493.3607 or 346.354.0950 for international callers (ID#: 9599904) or at the following address on the company’s website: investor.mylan.com. A replay of the webcast also will be available on the website.

Heska Corporation to Present at the Raymond James Annual Institutional Investors Conference

On February 18, 2020 Heska Corporation (NASDAQ: HSKA – News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, reported that Kevin Wilson, Heska’s President & Chief Executive Officer, will present at the Raymond James 41st Annual Institutional Investors Conference on Tuesday, March 3, 2020 at 9:50 a.m. ET in Orlando, FL (Press release, Heska, FEB 18, 2020, View Source [SID1234554471]).

Mr. Wilson will also be available for one-on-one meetings on March 3rd. To schedule a meeting, please contact Raymond James at [email protected] or Heska Investor Relations at [email protected].

A live webcast of the company’s presentation can be accessed at View Source

The webcast will be archived shortly after the event, and a replay will be available on the company’s website for 90 days following the conference. A copy of the presentation will be available on Heska’s website at View Source

Boston Scientific Announces February and March 2020 Conference Schedule

On February 18, 2020 Boston Scientific Corporation (NYSE: BSX) reported that it will participate in three upcoming investor conferences (Press release, Boston Scientific, FEB 18, 2020, View Source [SID1234554470]).

On February 27, 2020, Susie Lisa, vice president, Investor Relations, will participate in a 25-minute question-and-answer session with the host analyst at the SVB Leerink 9th Annual Global Healthcare Conference in New York City. The session will begin at approximately 10:30 a.m. EST.

On March 3, 2020, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa will participate in a 30-minute question-and-answer session with the host analyst at Cowen and Company’s 40th Annual Health Care Conference in Boston. The session will begin at approximately 10 a.m. EST.

On March 11, 2020, Mike Mahoney, chairman and chief executive officer, and Lauren Tengler, director, Investor Relations, will participate in a 25-minute question-and-answer session with the host analyst at the Barclays Global Healthcare Conference in Miami. The session will begin at approximately 8 a.m. EDT.

A live webcast and replay of the webcast for each event will be accessible at investors.bostonscientific.comView Source The replay will be available beginning approximately one hour following the completion of each event.

Phosplatin Therapeutics Announces Publication in OncoImmunology

On February 18, 2020 Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology drug development, reported its publication in OncoImmunology of in vitro and in vivo data demonstrating that PT-112 is a bona fide immunogenic cell death (ICD) inducer, and as a result can initiate anticancer immunity, as a monotherapy and in combination with immune checkpoint inhibition (Press release, Phosplatin, FEB 18, 2020, View Source [SID1234554469]).

PT-112 causes the release of so-called damage associated molecular patterns (DAMPs), a signature of ICD, by dying cancer cells. In addition, PT-112 synergizes with immune checkpoint blockers (ICBs) in the context of superior immune infiltration. These findings are in line with preliminary clinical evidence on the use of PT-112 in patients with solid tumors, either as a monotherapy or in combination with anti-PD-L1 immune checkpoint blockade.

"As a stand-alone agent, PT-112 has been validated as a potent ICD inducer," said Lorenzo Galluzzi, PhD, Assistant Professor of Cell Biology in Radiation Oncology at Weill Cornell Medical College, and senior author of the article. "Our model systems are designed to isolate the immune effects of a given agent, and PT-112 showed positive results across all model systems deployed thus far." "We have been delighted with our collaboration with Dr. Galluzzi and his laboratory team at Weill Cornell," said Matthew R. Price, Executive Vice President & COO at Phosplatin Therapeutics. "This publication underscores PT-112’s role within the emerging field of immunotherapy, and its potential as a best-in-class ICD inducer."

Along with ICD induction, PT-112 possesses a unique combination of factors, including safety in heavily pre-treated patients, single-agent activity in patients with lung cancers, prostate cancer and thymoma. In addition, the pyrophosphate component of the drug is believed to be responsible for bio-distribution that includes high drug concentrations in mineralized bone (osteotropism). PT-112’s features make it a promising candidate for the treatment of cancers that frequently metastasize to bone and/or are not likely to respond to checkpoint inhibitors.

Please refer to the OncoImmunology paper, "PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models," (Issue 9, Vol. 1) for the full description of the design and results of this work. The publication is available online here.

Further information on clinical trials with PT-112 that are currently open can be found at the clinicaltrials.gov registry under NCT 02266745, NCT 03409458, and NCT03288480.

About PT-112

PT-112 is a novel anti-cancer agent, the first cytotoxic small molecule conjugate of pyrophosphate developed in oncology therapeutics. PT-112 promotes immunogenic cell death (ICD), or the release of damage associated molecular patterns (DAMPs) that lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents a potential best-in-class small molecule inducer of this immunological form of cancer cell death. The first-in-human study of PT-112 demonstrated an attractive safety profile and evidence of long-lasting responses and tumor control among heavily pre-treated patients, and was presented at the ESMO (Free ESMO Whitepaper) 2018 Annual Congress, winning "Best Poster" among the Developmental Therapeutics category. The novelty of its pyrophosphate moiety also results in osteotropism, or the propensity of the drug to reach the mineralized bone. This property is of interest in cancer types that originate in bone, or frequently lead to metastatic bone involvement, such as metastatic castrate-resistant prostate cancer mCRPC. The first human clinical results in mCRPC were presented at the 2020 Genitourinary Cancers Symposium on February 13, 2020.

Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer

On February 18, 2020 Agendia, Inc., a world leader in precision oncology for breast cancer, reported that BMC Cancer published results from the IMPACt trial. The study measured changes in both treatment decisions and physician confidence when using the MammaPrint and BluePrint assays to support medical management for patients with early stage breast cancer (Press release, Agendia, FEB 18, 2020, View Source [SID1234554468]).

Because breast cancer is not a single disease, outcomes and response to therapy vary greatly from patient to patient based on biology that is not always reflected in standard clinical and pathologic features. Genomic testing has become more widely utilized to help understand these differences with the goal of improving patient outcomes. MammaPrint is a 70-gene signature that offers clarity on a patient’s risk of recurrence, whereas BluePrint is an 80-gene signature that goes beyond the surface of the tumor to identify the functional pathway driving its growth. The IMPACt study aimed to evaluate the role of genomic profiling in treatment planning as well as the degree of physician confidence when utilizing the MammaPrint and BluePrint assays.

"Through Agendia’s comprehensive genomic profiling tools, we are increasing our understanding of an individual’s tumor biology," stated Hatem Soliman, MD. "It is important to evaluate how that information impacts treatment planning in a real world clinical setting."

IMPACt prospectively enrolled 452 patients between November 2015 and August 2017. In the real-world cohort, MammaPrint and BluePrint reclassified 40% of pathologically subtyped tumors. This highlights the utility for a BluePrint molecular subtyping profile in early stage breast cancer and a more personalized approach to treatment for patients. The study also showed that physicians’ treatment plans for patients were consistent with their MammaPrint results in 89% of cases, supporting the use of this signature to inform treatment decisions in clinical practice. For clinically high risk patients for whom chemotherapy was initially recommended, there was a 60% reduction in the use of chemotherapy when patients were classified as Low Risk by MammaPrint. Conversely, when clinically low risk patients had a High Risk genomic profile, chemotherapy was added to the treatment plan in 60% of cases that did not initially include it.

Additionally, physicians reported greater confidence in their treatment decisions for 72% of cases after receiving MammaPrint results, supporting the findings of the 2015 PROMIS trial, which showed increased physician confidence in 79% of patient treatment plans. Both studies demonstrate a high level of certainty that patients are being offered chemotherapy when appropriate and reassurance that Low Risk patients can safely forego chemotherapy and its associated toxicities.

"Physician confidence is an integral component to determining the most effective treatment plan and provides much-needed peace of mind for our patients," says Robert Gabordi, MD.

"We are very encouraged with the results of this important trial confirming the clinical utility of MammaPrint and BluePrint," commented Agendia’s Chief Medical Officer, William Audeh, MD, MS. "This not only underscores the reliability of our genomic assays, but it further reinforces the critical role they play when optimizing a personalized treatment strategy for patients with early stage breast cancer."